NEEDHAM, Mass. & PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Tyrogenex, a privately held biopharmaceutical company, today announced plans to present at the 14th Annual BIO Investor Forum in San Francisco on Wednesday, Oct. 21, 2015, at 9:30 a.m. PDT in the Davidson room Ophthalmology track.
Tyrogenex is a biopharmaceutical company focused on developing a dual vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) inhibitor for wet age-related macular degeneration (wet AMD) and solid tumors.
Wet AMD is one of the leading causes of blindness for people over the age of 50, affecting over 1.5 million Americans. Current treatment options involve regular eye injections. Tyrogenex is working to provide an oral treatment option for wet AMD.
Last month, during the EURETINA Congress in Nice, France, Tyrogenex presented phase 1 data showing preliminary evidence of efficacy for X-82, Tyrogenex’s oral treatment and lead compound being evaluated for the treatment of wet AMD and solid tumors. Based on these results, Tyrogenex has initiated and is enrolling patients in the APEX phase 2 trial for the treatment of wet AMD.
Oncology clinical data from three studies and in vitro anti-CSF1R activity support the potential for X-82 to be used in combination therapy, particularly with checkpoint inhibitors.
The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and One-on-One PartneringTM meetings.
About Wet AMD
AMD is the leading cause of blindness for people over the age of 50 in the United States and Europe. There are two forms of the disease, namely "dry" and "wet" AMD. Wet AMD is characterized by the growth of new blood vessels into the central region of the retina. These new and abnormal blood vessels cause severe central vision loss due to retinal damage caused by leakage of the blood vessels and subsequent scar formation.
About X-82
Tyrogenex’s lead compound is X-82. X-82 inhibits both VEGF and PDGFR. Tyrogenex believes X-82 targets the basic mechanisms of neovascular eye diseases, including angiogenesis, fibrosis and inflammation. X-82 is currently being evaluated for wet AMD and solid tumors.
About Tyrogenex
Tyrogenex is a biopharmaceutical company focused on improving the lives of patients with wet AMD and solid tumors by discovering medicines to help provide additional treatment options. Tyrogenex’s lead compound is X-82. For more information, visit www.tyrogenex.com
Forward-Looking Statements
This press release contains forward-looking statements that are based on company management’s current beliefs and expectations and are subject to currently unknown information, risks and circumstances and actual results may vary from what is being currently projected.
